{"text": "of Clinical Psychopharmacology, approximately 1% of patients taking Abilify\n\nexperience suicidal thoughts or behaviors (2).\n\nNeuroleptic Malignant Syndrome (NMS)\n\nAbilify may increase the risk of neuroleptic malignant syndrome (NMS), a rare\n\nbut serious side effect. According to a study published in the Journal of\n\nClinical Psychopharmacology, approximately 0.1% of patients taking Abilify\n\nexperience NMS (3).\n\nTardive Dyskinesia\n\nAbilify may increase the risk of tardive dyskinesia, a rare but serious side", "embedding": []}